Investor profile
Elaia Partners
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Elaia is a European full-stack tech and deep tech investor that partners with ambitious entrepreneurs from inception to leadership, helping them navigate the future and the unknown. For over twenty years, the firm has combined deep scientific and technological expertise with decades of operational experience to back those building tomorrow. Elaia's Digital Venture funds cover all early stages from Pre-Seed to Series B, with tickets of €1m–€15m, focused on B2B tech companies across AI, cybersecurity, techbio, and industrial innovation. Its dedicated Deep Tech Seed funds (DTS series) back research-born startups — spin-offs from academic institutions or research-linked founders — in partnership with leading institutions such as PSL, INRIA, CNRS, and the Max Planck Foundation, with the conviction that breakthrough, IP-driven technology underpins entire sectors and delivers the strongest long-term returns.
Notable quotes
“Elaia's strategy has consistently delivered strong returns by focusing on complex, high-impact technologies going from AI and cybersecurity to Techbio or industrial innovation. Portfolio successes like Mirakl, Shift Technology, Vibe.co, iBanFirst, HarfangLab, Dexory, SeqOne etc. underscore our ability to spot disruptive potential at the early stage and turn it into market leadership.”
“For over 20 years, we've seen a recurring pattern in the market as in our previous funds: the best returns come from backing the technologies that underpin entire sectors. As a full-stack investor with a platform to invest across all stages, we are well-positioned with DV5 to build the next chapter in our mission to supercharge Europe's most resilient, high-growth companies.”
“At Elaia, we believe that the challenges that we are facing like the digitization of the world, climate change, or health issues can be solved by doing difficult things based on human knowledge and frontier knowledge. There is a lot of value to be created by backing research-based or research-linked companies.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Mirakl | Seed | — | 2012-01-01 |
| Criteo | Seed | — | 2008-01-01 |
| Shift Technology | Seed | — | 2015-01-01 |
| Alice & Bob | Series B | $110m | 2024-01-01 |
| Aqemia | Series A | — | 2023-01-01 |
| iBanFirst | Series B | — | 2020-01-01 |
| SESAMm | Series B | $39m | 2023-01-01 |
| Linkup | Seed | $11m | 2026-02-03 |
| Enodia Therapeutics | Seed | — | 2026-01-08 |
| Primaa | Series A | $8m | 2025-10-29 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Bpifrance | 25 |
| Partech | 10 |
| Idinvest Partners (Eurazeo) | 8 |
| Kima Ventures | 6 |
| Iris Capital | 5 |
| Sofinnova Partners | 4 |
Fit check
Is Elaia Partners a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit